12 citations
,
January 2004 in “Reproductive biomedicine online” This review discusses the main features of anti-androgen drugs, combined treatments, and insulin sensitizers in managing hirsutism and reports no new research findings.
4809 citations
,
January 2004 in “Fertility and Sterility” This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.
4025 citations
,
December 2003 in “Human Reproduction” This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.
192 citations
,
September 2003 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study suggests that metformin may be more effective than Dianette in treating moderate to severe hirsutism in women with PCOS, while also reducing markers of insulin resistance.
418 citations
,
June 2003 in “Endocrine Reviews” This review discusses the relationship between polycystic ovary syndrome and cardiovascular risk, noting a possible adverse impact on risk profiles and subclinical atherosclerosis but no clear increase in premenopausal cardiovascular events; it presents no new clinical results.
164 citations
,
January 2003 in “Drugs”
24 citations
,
March 2002 in “Expert opinion on investigational drugs” This review discusses various anti-androgen treatments for hirsutism, including androgen receptor blockers and inhibitors, and emphasizes the role of diagnosis in selecting the most appropriate therapy, but reports no new clinical results.
20 citations
,
January 1999 in “Current Pharmaceutical Design” This study reports that various antiandrogen therapies, including spironolactone and finasteride, effectively address hirsutism, acne, androgenic alopecia, and ovulatory dysfunction in hyperandrogenic women and are generally well tolerated.
49 citations
,
April 1997 in “Human reproduction” This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.
1947 citations
,
September 1995 in “New England journal of medicine/The New England journal of medicine” This article discusses the heterogeneity of polycystic ovary syndrome, its association with insulin resistance, and its implications for long-term health, but reports no new clinical results.
165 citations
,
February 1994 in “Fertility and Sterility” This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.
78 citations
,
May 1989 in “The Journal of Clinical Endocrinology & Metabolism” This study found that in hirsute women, daily treatment with 200 mg spironolactone significantly reduced hair growth rates and hair shaft diameters on various body areas over 12 months.
80 citations
,
January 1988 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study observed that high-dose spironolactone frequently caused metrorrhagia in women with idiopathic hirsutism, leading the authors to suggest lower starting doses or additional hormonal therapy.
64 citations
,
March 1984 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” In this study, cyproterone acetate combined with estradiol dramatically improved hirsutism symptoms and significantly reduced plasma testosterone and androstenedione levels in patients over periods of up to three years.
124 citations
,
September 1980 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that spironolactone significantly reduced hair growth in hirsute women, with noticeable effects in 3-5 months, and decreased serum testosterone levels in all participants.